Table 1.
Cohort Demographic and Clinical Characteristics (n=121)
| Black/African American |
Non-Hispanic White | White Hispanic | Overall | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Total (n=41) |
Men (n=20) |
Women (n=21) |
Total (n=41) |
Men (n=21) |
Women (n=20) |
Total (n=39) |
Men (n=20) |
Women (n=19) |
Total (n=121) |
Total Men (n=61) |
Total Women (n=60) |
|
| Age | ||||||||||||
| Mean ± S.D. (Range) | 49.8 ±10.6 (23-68) | 51.6 ±7.12 (34-62) | 48.1 ±13.04 (23-68) | 51.0 ±9.4 (26-67) | 52.8 ±7.70 (40-67) | 49.1 ±10.65 (26-64) | 47.8 ±8.6 (29-66) | 49.4 ±7.88 (37-66) | 46.1 ±9.22 (29-59) | 49.5 ±9.6 (23-68) | 51.3 ±7.6 (34-67) | 47.8* ±11.0 (23-68) |
| Education Level | ||||||||||||
| Less than HS | 15 | 4 | 11 | 6 | 2 | 4 | 15 | 5 | 10 | 36 | 11 | 25 |
| HS grad | 7 | 4 | 3 | 8 | 1 | 7 | 10 | 6 | 4 | 25 | 11 | 14 |
| At least some college | 18 | 11 | 7 | 27 | 18 | 9 | 14 | 9 | 5 | 59 | 38* | 21 |
| Years since Diagnosis | ||||||||||||
| Mean ± S.D. (Range) | 15.2 ±8.1 (1-29) | 15.1 ±7.81 (1-22) | 15.3 ±8.47 (1-29) | 15.5 ±8.9 (2-31) | 17.3 ±9.63 (3-31) | 13.8 ±7.91 (2-26) | 10.7¶ ±5.3 (1-20) | 10.7 ±5.55 (1-20) | 10.7 ±5.10 (1-20) | 13.8 ±7.8 (1-31) | 14.3 ±8 (1-31) | 13.3 ±7 (1-29) |
| CD4 T Cell Count | ||||||||||||
| Mean/mm3 ± S.D. (Range) | 662.6 ±270.4 (97-1254) | 601.8 ±300.4 (97-1254) | 720.6 ±230.8 (315-1166) | 638.0 ±372.9 (145-1799) | 531.76 ±353.3 (145-1799) | 749.45 ±368.5 (183-1381) | 643.7 ±337.7 (97-1399) | 573.05 ±304.1 (97-1275) | 714.36 ±362.6 (218-1399) | 648.2 ±327.0 (97-1799) | 568.2 ±316.9 (97-1799) (97-1799) | 728.3* ±319.6 (183-1399) |
| Viral Load, copies/mL | ||||||||||||
| <20 | 35 | 14 | 21 | 33 | 18 | 15 | 33 | 15 | 18 | 101 | 47 | 54 |
| >20 | 6 | 6 | 0 | 7 | 3 | 4 | 5 | 4 | 1 | 18 | 13 | 5 |
| ART CPE score | ||||||||||||
| Mean ± S.D. (Range) | 6.4 ±3.7 (0-14) | 6.4 ±3.7 (0-12) | 6.5 ±3.7 (0-14) | 7.4 ±3.3 (0.16) | 8.1 ±3.0 (3-16) | 6.5 ±3.4 (0-11) | 7.3 ±3.2 (0-16) | 7.6 ±2.3 (0-13) | 6.5 ±3.9 (0-16) | 7.0 ±3.4 (0-16) | 7.4 ±3.1 (0-16) | 6.6 ±3.6 (0-16) |
| Comorbidities | ||||||||||||
| CNS | 9 | 5 | 4 | 11 | 5 | 6 | 6 | 1 | 5 | 26 | 11 | 15 |
| Coin-fections | 14 | 8 | 6 | 25 | 14 | 11 | 13 | 8 | 5 | 52 | 30 | 22 |
| Psychiatric | 20 | 6 | 14 | 11 | 3 | 8 | 23 | 9 | 14 | 54 | 18 | 35 |
| Respiratory | 19 | 9 | 10 | 16 | 6 | 10 | 12 | 4 | 8 | 47 | 19 | 28 |
| Cardiac | 23 | 16 | 17 | 24 | 14 | 10 | 22 | 12 | 10 | 69 | 42 | 37 |
| Endo-crine, Liver & Kidney | 20 | 8 | 12 | 18 | 5 | 13 | 7 | 3 | 4 | 45 | 16 | 29 |
| Cancer | 1 | 1 | 0 | 9 | 4 | 5 | 1 | 1 | 0 | 11 | 6 | 9 |
| Tx for Drug & Alcohol | 10 | 5 | 5 | 12 | 2 | 10 | 5 | 2 | 3 | 27 | 9 | 18 |
Abbreviations: ART, antiretroviral therapy; CPE, CNS penetration effectiveness; HS, high school, Tx for Drug and alcohol, Past treatment for drug and alcohol abuse.
¶
Significance for sex comparisons by t-test, and
*
race/ethnic comparisons by one-way ANOVA or Chi χ2 for categorical variables. Missing data: Education level, one Black/African American man; one viral load, Non-Hispanic White woman, and one White Hispanic man.